MTZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MasTec (MTZ) is not a clear buy right now for a beginner long-term investor, despite strong analyst support and bullish long-term growth targets. The stock is trading below its pivot with weak near-term momentum, and without a strong Intellectia buy signal, the best call today is to hold and wait rather than buy immediately at this level.
MTZ is in a mixed-to-weak short-term technical position. MACD histogram is -6.108 and still below zero, which signals bearish momentum even though it is contracting. RSI_6 at 36.032 is neutral-to-weak, not yet oversold enough to imply a strong rebound signal. Moving averages are converging, suggesting a potential trend inflection, but the price at 384 is still below the pivot of 399.548. Immediate support is near S1 at 374.011, with stronger support at S2 at 358.235, while resistance sits at R1 425.085 and R2 440.861. Overall, the chart does not currently confirm an attractive entry for an impatient buyer.
The company’s analyst day appears to have reinforced confidence in a multi-year growth story. Key positives from analyst commentary include record backlog, strong revenue visibility into late 2027, projected 2028 targets of roughly 15% revenue CAGR, 25% EBITDA CAGR, and 30% EPS CAGR, plus significant free cash flow and borrowing capacity. These are strong long-term catalysts for MasTec.
The news summary provided is unrelated to MTZ and does not supply any direct positive event-driven catalyst for the stock. Technically, the stock still shows negative momentum with MACD below zero and price below pivot. Hedge funds and insiders are neutral, so there is no supportive trading trend from those groups. There is also no recent congress trading activity to add confidence. The pattern-based outlook suggests a 60% chance of a -1.46% move next day, which weakens the short-term entry case.
Latest quarter shown in the data is Q1 2026. The company beat expectations, raised full-year guidance, and posted record March backlog around $20 billion, indicating strong growth momentum and improving revenue visibility. Analysts highlighted stronger topline performance across segments and better-than-expected pipeline margins. This quarter supports a constructive long-term growth thesis, especially for backlog-driven revenue expansion.
Recent analyst trends are clearly positive. Guggenheim upgraded MTZ to Buy with a $480 target, KeyBanc raised its target to $500, JPMorgan lifted its target to $491, Clear Street raised to $500, Mizuho to $498, Stifel to $455, Jefferies to $493, Truist to $518, and Roth Capital to $450. The overall Wall Street view is bullish, with multiple Buy/Outperform/Overweight ratings and rising price targets. The bull case is strong multi-year growth, record backlog, and improved margins. The bear case is that the stock has already rallied into optimistic expectations and near-term technicals are not confirming fresh upside.
